CONTACT
+91 80 2808 2808
info@biocon.com
Biocon  /  Businesses  /  Biosimilars  /  Partners

BIOCON BIOSIMILARS

Partners

null

Biocon Biologics proactively seeks innovative partnerships to improve the biologics experience of patients, providers and payers.

Strategic global and regional partnerships allow us to share risks, lower costs, maximise efficiencies, expedite development, and commercialise products in various global markets, to deliver innovative and inclusive healthcare solutions. We also develop molecules independently. We have a long standing, successful global partnership with Mylan for a range of biosimilar antibodies and insulin analogs. Our global partnership with Sandoz (a division of Novartis) will prepare us for the next wave of biosimilar opportunities. Our product pipeline of 28 molecules includes 11 partnered with Mylan, several with Sandoz and many being developed independently. Strong regional partnerships with local companies in key emerging markets help us overcome local resource and knowledge gaps. It also provides access to local commercial capabilities and distribution networks, and helps understand local stakeholders including prescribing physicians.

To partner with us, write to:

Gaurav Laroia

Chief Strategy Officer & Head of Business Development

E gaurav.laroia@biocon.com

CONTACT US >>
CORPORATE GOVERNANCE
KEY THERAPEUTIC AREAS
RESEARCH SERVICES
OUR CULTURE
RESPONSIBILITY
Share